This article has been updated to clarify Veracyte's copromotion arrangement with Sanofi Genzyme.
NEW YORK (GenomeWeb) – Veracyte announced after the close of the market Wednesday a 23 percent rise in its second quarter revenues as the company continued to experience increased demand for its Afirma gene expression classifier thyroid test.